Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Dr. Reddy’s Expands Global Reach of Nerivio® Migraine Management Device with European Launch After Successful Introduction in India

NextEdge Admin

12 Apr 2024

2 min 27 sec

Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, has introduced the drug-free non-invasive migraine management wearable device Nerivio® to the German market through its subsidiary betapharm, marking its entry into digital therapeutics in Europe. Nerivio® is both FDA-approved in the United States and CE-mark certified in Europe. The device was showcased at prominent neurological conferences in 2023 and will be launched at the Neurological Association of South Africa annual congress in April 2024, followed by presentations at the International Headache Society meeting in Berlin. Dr. Reddy’s plans to expand Nerivio®’s availability to Spain and the UK in the coming months.

Under an exclusive agreement with Theranica, Dr. Reddy’s is marketing and distributing Nerivio® in multiple markets. Migraine affects a significant portion of the global population, with a particularly high impact on women. In India, where Nerivio® was launched in 2023, Dr. Reddy’s offers the ‘M-Free’ patient support program, providing comprehensive assistance such as onboarding, counseling, device demonstrations, and lifestyle modification recommendations.

M.V. Ramana, CEO of Branded Markets, emphasized Nerivio®’s potential to address the unmet clinical needs of migraine patients, reduce pill burden, and improve patient outcomes. Nerivio® has demonstrated its effectiveness in benefiting over 45,000 patients globally, supported by extensive clinical evidence involving more than 19,000 patients as both an acute and preventive treatment option for migraine. Dr. Reddy’s is eager to gather feedback from patients and healthcare professionals in the newly targeted markets, building on Nerivio®’s success and its contribution to migraine management globally.